Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia

A compound of formula 1

• or a pharmaceutically acceptable salt thereof, wherein in formula 1:
• R1 is a group selected from formula (i) or formula (ii), below:
• and wherein:
• A is —(CH2)mCH2—, —(CH2)mO—, or —(CH2)mNH—, wherein m is an integer from 3 to 5, wherein two of the carbon atoms of —(CH2)mCH2— are optionally linked by a double bond, and wherein one or two of the carbon or nitrogen atoms of —(CH2)mCH2—, —(CH2)mO—, and —(CH2)mNH— can be substituted, optionally and independently, with a methyl or ethyl;
• D is N, C, or CH, provided that when D is N, each carbon atom attached to D is attached through a single bond;
• J and K are independently selected from N, CH, and C;
• Q, Y, and Z are independently selected from N or C;
• V and W are independently N, C, or CH;
• ring AA is a saturated or unsaturated 5- 6- or 7-membered carbocyclic ring wherein one, two or three of the carbon atoms of ring AA that are not shared with the 6-membered aryl ring of group (ii) can be replaced, optionally and independently, by a nitrogen, oxygen or sulfur atom;
• R1, R2 and R3 are independently selected from hydrogen, halo, cyano, hydroxy, (C1-C4) alkyl, and (C1-C4) alkoxy, wherein the alkyl moieties of the (C1-C4) alkyl or (C1-C4) alkoxy are straight or branched and can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent, provided that when Q is N, R1 is absent and when Y is N, R is absent;
• R4, R5, R6, R7, R8, and R9 are independently selected from hydrogen, fluoro, hydroxy, (C1-C4) alkyl, and (C1-C4) alkoxy, wherein the alkyl moieties of the (C1-C4) alkyl or (C1-C4) alkoxy are straight or branched;
• provided that when Z is N, R8 cannot be fluoro or hydroxy;
• R10 is independently selected from hydrogen, (C1-C4) alkyl, and (C1-C4) alkoxy, wherein the alkyl moieties of the (C1-C4) alkyl or (C1-C4) alkoxy are straight or branched;
• R11, R12, R13, R14, and R15 are independently selected from hydrogen, halo, —(═O)CH3, (C1-C4) alkyl, and (C1-C4) alkoxy, aryl, and aryloxy, wherein the alkyl moieties of the (C1-C4) alkyl, (C1-C4) alkoxy, and —C(═O)CH3 groups and the aryl and aryloxy moieties can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent;
• R16 and R17 are independently selected from hydrogen, halo, cyano, oxo, hydroxy, —C(═O)CH3, (C1-C4) alkyl, and (C1-C4) alkoxy, wherein the alkyl moieties of the (C1-C4) alkyl, (C1-C4) alkoxy, and —C(═O)CH3 groups can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent;